APA (7th ed.) Citation

B, Y., C, P., LJ, C., EM, S., MA, B., G, F., . . . RA, B. (2022). Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 40(34), 3965. https://doi.org/10.1200/JCO.22.01207

Chicago Style (17th ed.) Citation

B, You, et al. "Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 40, no. 34 (2022): 3965. https://doi.org/10.1200/JCO.22.01207.

MLA (9th ed.) Citation

B, You, et al. "Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 40, no. 34, 2022, p. 3965, https://doi.org/10.1200/JCO.22.01207.